Table 3.
Clinical and pathological features of sinonasal NUT carcinoma reported in the literature.
| Year | Age (years) | Sex | Location | Metastasis | Therapy | Outcome | Follow-up (months) | Tests | Positive tests | Negative tests |
|---|---|---|---|---|---|---|---|---|---|---|
| 2004 (2) | 26 | M | Sinonasal | Bone | CRT | Alive | 67 | IHC + FISH | CD34, NUT | PLAP |
| 2009 (22) | 31 | M | Nasal cavity | LNs | CRT + S | DOD | 10 | / | / | / |
| 39 | F | Nasal cavity, frontal sinus | LNs | CRT + S | DOD | 7 | / | / | / | |
| 2008 (23), 2010 (19) | 31 | M | Nasal cavity | / | / | / | / | IHC + FISH | p63, NUT | / |
| 39 | F | Nasal cavity, frontal sinus | / | / | / | / | IHC + FISH | p63, NUT | / | |
| 40 | F | Nasal cavity and maxillary, frontal sinuses | / | / | / | / | IHC + FISH | p63, NUT | / | |
| 47 | M | Nasal cavity, ethmoid sinus | / | / | / | / | IHC + FISH | p63, NUT | / | |
| 2012 (9) | 26 | M | Paranasal sinus | LNs | S + CRT | DOD | / | TMA + IHC | NUT, AE1/AE3 | / |
| 33 | M | Paranasal sinus | Yes | S + CRT | DOD | / | TMA + IHC | NUT, AE1/AE3 | / | |
| 48 | M | Paranasal sinus | Yes | S + CRT | DOD | / | TMA + IHC | NUT, AE1/AE3 | / | |
| 56 | F | Sinonasl tract | LNs | / | / | / | IHC + FISH | NUT | / | |
| 36 | F | Sinonasl tract | Bone | / | / | / | IHC + FISH | NUT | / | |
| 2011 (22) | 54 | F | Right nasal dorsum | LN | CRT | DOD | 7 | CA + IHC + FISH | Vimentin, CAM 5.2, NUT | S100, CD99, NSE, CD56, SYN, myogenin, myo-D1, Desmin, CD45 |
| 2019 (1) | 39 | F | Paranasal sinus | / | / | / | / | FISH | CAM5.2, SYN | Pankeratin |
| 49 | M | Frontal sinus | / | / | / | / | FISH | p63, CK5/6, CK7, p16 | TTF1, SYN, CHR | |
| 48 | M | Ethmoid sinus | / | / | / | / | FISH | AE1/AE3, EMA | SYN, CHR, TTF1, GFAP | |
| 67 | F | Nasal, maxillary sinus | / | / | / | / | FISH | p63, SYN | CHR, S100, CD99, CK7, CK5/6, Desmin, CD34 | |
| 2015 (24) | 26 | M | Left maxillary sinus, nasal cavity | / | S + CRT | DOD | 18 | IHC | NUT, CK AE1/3, CD99 (focal) | p63, CHR, Desmin, S100, EBV- ISH |
| 2011 (17) | 54 | F | Left paranasal sinus | / | CRT + S | / | / | IHC + FISH | CK7, p63, NSE (+/−), NUT | EBV- ISH, S100, CD45, SYN, CHR-A, CK 20, CD34 |
| 2014, 2018 (16, 18) | 18 | F | Right nasal cavity and maxillary, ethmoidal sinuses | / | CRT | AWD | 12 | IHC + FISH + CA + RT-PCR | CD138 (foacl), AE1/3, EMA, p63, p40 (focal), Vimentin, NUT, Myc | S100, CD34, CD99, SYN, myogenin, PLAP, c-kit, hCG, CAM5.2, CK5/6, CGNA, SYN, CD56, Desmin, CD45RB, NKX2.2, TdT, p16, EBER-ISH |
| 56 | F | Left nasal cavity, ethmoidal sinus, nasopharynx | Liver, lungs, pleura, spleen, adrenal glands, LNs, and bones | CRT | DOD | 10 | IHC + FISH + RT-PCR | CAM5.2, p63, p40 (focal), vimentin, NUT, Myc, CD56 (focal) | AE1/AE3, EMA, CK5/6, CD34, CGNA, SYN, S100, Desmin, CK45RB, NKX2.2, TdT, p16, EBER-ISH | |
| 66 | F | Frontal sinus | Liver and bones | CRT | DOD | 13 | IHC + FISH + RT-PCR | AE1/AE3 (focal), CAM5.2, EMA, p63, p40, Vimentin, NUT, Myc, CD34, CD56 (focal) | CK5/6, CGNA, SYN, S100, Desmin, CD45RB, NKX2.2, TdT, p16, EBER-ISH | |
| 0.75 | M | Bilateral nasal cavities, maxillary sinuses | Lungs, kidneys, bone, thyroid, liver, left adrenal gland, pancreas, right submandibular gland, and LNs | CRT | DOD | 15 | IHC + FISH + RT-PCR | AE1/AE3 (focal), p63, p40 (focal), Vimentin, NUT, Myc | CAM5.2, EMA, CK5/6, CD34, CGNA, SYN, CD56, S100, Desmin, CD45RB, NKX2.2, TdT, P16, EBER-ISH | |
| 2020 (8) | 60 | F | Right maxillary sinus | Yes | RT + S | DOD | 12 | IHC | Pan-CK, p63, p40, CD99 (focal weak), NUT | CD34, CD56, p16, EBV-ISH |
| 45 | F | Left ethmoid sinus | No | S + CRT | NETR | 36 | IHC | Pan-CK, p63, p40, p16, NUT | CD34, CD56, EBV-ISH, CD99, HPV genotype PCR | |
| 42 | M | Right ethmoid sinus | Yes | CRT. | R | / | IHC | Pan-CK, p63, p40, CD99 (focal weak), NUT | CD34, CD56, p16, EBV-ISH | |
| 29 | M | Right ethmoid sinus | No | S + CT | / | / | IHC + FISH | Pan-CK (focal), p63, CD99 (focal), NUT | CD34, CD56 | |
| 2015 (25) | 14 | F | Right nasal cavity, anterior ethmoid sinus | / | S + RT | DOD | 3 | IHC + FISH | NUT | / |
| 2018 (26) | 30 | M | Left sinonasal | / | / | / | / | IHC | CK, NUT, p40, p16 (focal) | CD34 |
| 31 | F | Left nasal cavity and ethmoid, sphenoid, maxillary sinuses | / | CRT + S | DOD | 2 | IHC | NUT, p40, p16 (focal), CD34, p16 (focal) | / | |
| 25 | M | Right nasal cavity | / | / | / | / | / | CK, NUT, p40, p16 (focal) | SYN | |
| 10 | F | Left nasal cavity, left lacrimal sac | / | S + CRT | / | / | / | NUT, p16 | ||
| 30 | F | Left nasal cavity, maxillary sinus, orbit | / | / | / | / | / | Pan-CK, p40, NUT, p16 (focal) | SYN, EBV-LMP | |
| 2017 (14) | 20 | M | Left ethmoid sinus, orbit | No | CRT + S | DOD | 22 | IHC + RT-PCR | AE1/AE3, CK, NUT | TTF1, Desmin, myogenin, CD45, CD34 |
| 2016 (27) | 20 | M | Sinonasal | / | S + CRT | DOD | 22 | FISH | AE1/AE3, CK14, CK5/6 | SYN, CHR-A, CD56, S100 |
| 2017 (28) | 53 | M | Left nasal cavity | No | S + CRT | DOD | 3 | IHC + FISH | CK5/6, p16, p40, p63, NUT, CK20 (focal), SYN | CD34, S100 |
| 2018 (29) | 49 | M | Left nasal cavity and maxillary, ethmoid, frontal sinuses; right frontal sinus | Bone, LNs | CRT + S | DOD | 9 | IHC + CA | CD99, NUT, CAM5.2, S100 (focal) | AE1/AE3, CD3, CD20, CD56, SYN, Desmin, myoglobin |
| 2021 (30) | 56 | F | Right nasal cavity | / | S + CRT | DOD | 6 | IHC | pankeratin, p16, p53, NUT | / |
| 2020 (31) | 44 | M | / | / | / | / | / | IHC | NUT | / |
| 2018 (32) | 48 | M | Left nasal cavity | / | S + CRT | DOD | / | MGT | Monokerati, p63, CD34, p16 | S100, HMB45, leukocyte common antigen, CHR, SYN, EBV-ISH |
| 2019 (33) | 48 | M | Left sphenoidal sinus | / | S + CRT | Alive | 6 | IHC + targeted RNA sequencing | NUT, AE1/3, CK5/6, p40, Ki67 (60%), SYN (weak), p16 (weak) | CHR-A, Desmin, S100, EBV-LMP |
| 2021 (34) | 39 | M | Sinonasal | Lung | S + CRT + BETi | Alive | 21 | IHC + whole transcr-ipto-mic RNA sequencing | AE1/AE3, CK5, p40 (focal), NUT | TTF1, Napsin-A, SYN, CHR-A, smooth muscle actin, p16, S100, EBV-ISH |
| 2015 (35) | 29 | F | Left maxillary sinus | LNs | S + CRT | / | / | / | p16 (partial) | EBER |
| 2018 (36) | 60 | F | Nasal cavity | / | S + RT | DOD | 3 | IHC + FISH | NUT, CK5/6, CK7, p16, p40, p63, SMARCB1 (INI1), Vimentin, Ki-67 (95%) | CD34, CD56, CHR, S100, SYN |
| 65 | M | Nasal cavity | / | S + RT | Alive | 108 | IHC + FISH | NUT, CK5/6, EMA, CK7, p16, p40, p63, SMARCB1 (INI1), Vimentin, ki-67 (95%) | CD34, CD56, CHR, S100, SYN | |
| 46 | M | Maxillary sinus | / | S + RT | DOD | 8 | IHC + FISH | NUT, CK5/6, EMA, p16, p40, p63, SMARCB1 (INI1), Vimentin, Ki-67 (95%) | CD34, CD56, CHR, S100, SYN | |
| 2022 (37) | 60 | F | Right sinonasal tract | / | S + RT | Alive | 5 | IHC + FISH | NUT, p63, CK5/6 (focal), p40 (focal), AE1/AE3 | CHR-A, CD56, CD45RO, NKX2.2, p16, Vimentin, S100 |
| 2013 (38) | 55 | M | Sinonasal | Intracranial, orbit | RT | AWD | 40 | IHC + FISH | NUT, CK7, CK8, p63 | / |
| 42 | M | Sinonasal | Intracranial, orbit | RT + CRT | DOD | 12 | IHC + FISH | NUT, CK7, CK8, p63 | / | |
| 59 | F | Nasal cavity | / | RT | AWD | 12 | IHC + FISH | NUT, CK7, CK8, p63 | / | |
| 50 | M | Sinonasal | Intracranial | / | DOD | 1 | IHC + FISH | NUT, CK8, p63 | / |
AWD, alive with disease; CA, chromosome analysis; CHR, chromogranin; CK, cytokeratins; CRT, chemoradiation therapy; CT, chemotherapy; DOD, died of disease; EBV-ISH, Epstein-Barr virus (EBV) in situ hybridization; LNs, lymph nodes; MGT, molecular genetic testing; NA, not available; NETR, no evidence of tumor recurrence; NSE, neuron-specific enolase; Pan-CK, pancytokeratin; PLAP, placental alkaline phosphatase; R, recurrence; RT, radiotherapy; S, surgery; SYN, synaptophysin; TMA, tissue microarrays.